She is probably at 50 pills a day to maintain her health.
I want to add, if I may backtrack—sorry—to what the issue is here as we talk about pharmaceutical companies coming here, and as Mr. McKinnon said. You asked about the cost. The pharmaceutical companies are two steps ahead of us. The other downfall is that when it comes to these rare disease markets and there are only 75 patients to sell something to, I wouldn't start a business to sell something to 75 people.
What they'll do is they'll come in under SAP as well. The pharma companies want to offer that compassionate usage of their products until they are approved so that we have something rather than nothing, but then, in all the fine print, they say that once a patient comes under their compassionate care, they remain there. Even when it's approved, the insurance companies won't pick up the cost because the company has already agreed. If a company comes in and offers our daughter a new product and, say, 35 people go on SAP, they don't have many patients to continue to build a business offer.
I think it's important to add to that, because it's another really big issue with pharma companies wanting to work with us as well as trying to build a business, make a profit and potentially hopefully continue to give back to rare disease communities.